Wenqin L. Luo

Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 62 publications

Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial.

Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 29, 2026

PTPRN2-mediated silencing of tumor-intrinsic MHC-II promotes immune-excluded tumor microenvironment in colorectal cancer.

PTPRN2-mediated silencing of tumor-intrinsic MHC-II promotes immune-excluded tumor microenvironment in colorectal cancer.

Journal: Cancer genetics

Published: March 27, 2026

Correction: N6‑methyladenosine‑modified TRAF1 promotes sunitinib resistance by regulating apoptosis and angiogenesis in a METTL14‑dependent manner in renal cell carcinoma.

Correction: N6‑methyladenosine‑modified TRAF1 promotes sunitinib resistance by regulating apoptosis and angiogenesis in a METTL14‑dependent manner in renal cell carcinoma.

Journal: Molecular cancer

Published: March 03, 2026

Functional precision oncology platform of BRAFV600E-mutated colorectal cancer organoids predicts therapy response and reveals RNF43-mediated immunogenicity.

Functional precision oncology platform of BRAFV600E-mutated colorectal cancer organoids predicts therapy response and reveals RNF43-mediated immunogenicity.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: February 22, 2026

PDK4-driven metabolic reprogramming enhances mesothelial cell invasion in colorectal cancer peritoneal metastasis.

PDK4-driven metabolic reprogramming enhances mesothelial cell invasion in colorectal cancer peritoneal metastasis.

Journal: Acta biochimica et biophysica Sinica

Published: January 29, 2026

ALYREF-mediated m5C modification of CCNA1 drives escape from cell-cycle arrest and contributes to pazopanib resistance in Renal Cell Carcinoma.

ALYREF-mediated m5C modification of CCNA1 drives escape from cell-cycle arrest and contributes to pazopanib resistance in Renal Cell Carcinoma.

Journal: International journal of biological sciences

Published: January 13, 2026

Circular RNA-based therapy targeting metabolic vulnerability of fatty acid synthesis overcomes castration-resistant prostate cancer.

Circular RNA-based therapy targeting metabolic vulnerability of fatty acid synthesis overcomes castration-resistant prostate cancer.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: December 30, 2025

PUS1 Drives Renal Cancer Progression by Preventing Formation of Endogenous Double-stranded RNAs.

PUS1 Drives Renal Cancer Progression by Preventing Formation of Endogenous Double-stranded RNAs.

Journal: International journal of biological sciences

Published: December 18, 2025

Correction: Han et al. Enhanced De Novo Lipid Synthesis Mediated by FASN Induces Chemoresistance in Colorectal Cancer. Cancers 2023, 15, 562.

Correction: Han et al. Enhanced De Novo Lipid Synthesis Mediated by FASN Induces Chemoresistance in Colorectal Cancer. Cancers 2023, 15, 562.

Journal: Cancers

Published: November 25, 2025

TLR8 agonists remodel the tumor immune microenvironment through PF4-dependent T cell recruitment and ancillary mechanisms.

TLR8 agonists remodel the tumor immune microenvironment through PF4-dependent T cell recruitment and ancillary mechanisms.

Journal: Cancer immunology, immunotherapy : CII

Published: September 12, 2025

Multi-omics analysis of patient-derived organoids reveals that E3 ligase COP1 promotes liver metastasis and oxaliplatin resistance in colorectal cancer through LUZP1 degradation and MYL9 phosphorylation.

Multi-omics analysis of patient-derived organoids reveals that E3 ligase COP1 promotes liver metastasis and oxaliplatin resistance in colorectal cancer through LUZP1 degradation and MYL9 phosphorylation.

Journal: Experimental hematology & oncology

Published: September 09, 2025

Cepharanthine triggers immunogenic cell death in solid tumors by suppressing protein kinase C zeta-mediated poly(ADP-ribose) polymerase 1 expression and synergizes with immunotherapy.

Cepharanthine triggers immunogenic cell death in solid tumors by suppressing protein kinase C zeta-mediated poly(ADP-ribose) polymerase 1 expression and synergizes with immunotherapy.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Published: September 04, 2025

Showing 1-12 of 62

Last Updated: 09/26/2026